Branded Legacy, Inc. to Acquire Bio-Legacy Evaluative Group, Expanding into Intranasal Drug Delivery Market
Branded Legacy, Inc. (OTC: BLEG) has signed a Letter of Intent to acquire Bio-Legacy Evaluative Group, marking a strategic expansion into the intranasal drug delivery sector with a focus on addiction treatments and vaccine accessibility.
Branded Legacy, Inc. (OTC: BLEG), a company dedicated to health and wellness solutions, has taken a significant step towards expanding its portfolio by signing a non-binding Letter of Intent to acquire Bio-Legacy Evaluative Group. This acquisition, valued at $1.5 million in Preferred D stock, is poised to transfer all of Bio-Legacy's equity, assets, and intellectual property to Branded Legacy. The move is strategic, aiming to position Branded Legacy in the rapidly growing markets of addiction treatments and vaccine accessibility, leveraging Bio-Legacy's advanced intranasal drug delivery technologies.
The acquisition is particularly notable for Bio-Legacy's patented naloxone device, which addresses critical challenges in cost and dosing within a market expected to surpass $1.16 billion by 2032. Post-acquisition, Amin Janmohamed, CEO of Bio-Legacy, is set to lead Branded Legacy as its new CEO and Chairman. The company has outlined ambitious plans, with manufacturing prototyping targeted for the third quarter of 2025 and the naloxone device anticipated to be market-ready by the first quarter of 2027.
This development underscores Branded Legacy's commitment to innovation and strategic growth in the biotech and wellness sectors. By integrating Bio-Legacy's pioneering technologies, Branded Legacy is not only expanding its product offerings but also enhancing its capability to make a meaningful impact in critical healthcare areas. For more details on the acquisition, visit https://ibn.fm/5kuAK.